vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Real Brokerage Inc (REAX). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $568.5M, roughly 1.7× Real Brokerage Inc). Astrana Health, Inc. runs the higher net margin — 0.7% vs -0.1%, a 0.8% gap on every dollar of revenue. On growth, Real Brokerage Inc posted the faster year-over-year revenue change (52.6% vs 42.9%). Real Brokerage Inc produced more free cash flow last quarter ($8.4M vs $-6.0M).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Anywhere Real Estate Inc., formerly Realogy, was an American real estate services firm. It operated and franchised real estate brands that provided brokerage, relocation, title, insurance, and settlement services. Brands included Better Homes and Gardens Real Estate, Century 21 Real Estate, Coldwell Banker, Corcoran Group, ERA Real Estate and Sotheby's International Realty. In 2026, the company was acquired by Compass, Inc.

ASTH vs REAX — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.7× larger
ASTH
$950.5M
$568.5M
REAX
Growing faster (revenue YoY)
REAX
REAX
+9.7% gap
REAX
52.6%
42.9%
ASTH
Higher net margin
ASTH
ASTH
0.8% more per $
ASTH
0.7%
-0.1%
REAX
More free cash flow
REAX
REAX
$14.4M more FCF
REAX
$8.4M
$-6.0M
ASTH

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ASTH
ASTH
REAX
REAX
Revenue
$950.5M
$568.5M
Net Profit
$6.6M
$-447.0K
Gross Margin
7.9%
Operating Margin
1.9%
-0.1%
Net Margin
0.7%
-0.1%
Revenue YoY
42.9%
52.6%
Net Profit YoY
184.4%
82.7%
EPS (diluted)
$0.12
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
REAX
REAX
Q4 25
$950.5M
Q3 25
$956.0M
$568.5M
Q2 25
$654.8M
$540.7M
Q1 25
$620.4M
$354.0M
Q4 24
$665.2M
Q3 24
$478.7M
$372.5M
Q2 24
$486.3M
Q1 24
$404.4M
$200.7M
Net Profit
ASTH
ASTH
REAX
REAX
Q4 25
$6.6M
Q3 25
$373.0K
$-447.0K
Q2 25
$9.4M
$1.5M
Q1 25
$6.7M
$-5.0M
Q4 24
$-7.8M
Q3 24
$16.1M
$-2.6M
Q2 24
$19.2M
Q1 24
$14.8M
$-16.1M
Gross Margin
ASTH
ASTH
REAX
REAX
Q4 25
Q3 25
7.9%
Q2 25
8.9%
Q1 25
9.6%
Q4 24
Q3 24
8.6%
Q2 24
Q1 24
10.3%
Operating Margin
ASTH
ASTH
REAX
REAX
Q4 25
1.9%
Q3 25
2.0%
-0.1%
Q2 25
3.1%
0.3%
Q1 25
3.3%
-1.5%
Q4 24
0.1%
Q3 24
5.9%
-0.7%
Q2 24
6.2%
Q1 24
7.5%
-7.8%
Net Margin
ASTH
ASTH
REAX
REAX
Q4 25
0.7%
Q3 25
0.0%
-0.1%
Q2 25
1.4%
0.3%
Q1 25
1.1%
-1.4%
Q4 24
-1.2%
Q3 24
3.4%
-0.7%
Q2 24
3.9%
Q1 24
3.7%
-8.0%
EPS (diluted)
ASTH
ASTH
REAX
REAX
Q4 25
$0.12
Q3 25
$0.01
$0.00
Q2 25
$0.19
$0.01
Q1 25
$0.14
$-0.02
Q4 24
$-0.14
Q3 24
$0.33
$-0.01
Q2 24
$0.40
Q1 24
$0.31
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
REAX
REAX
Cash + ST InvestmentsLiquidity on hand
$429.5M
$38.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$53.6M
Total Assets
$2.2B
$145.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
REAX
REAX
Q4 25
$429.5M
Q3 25
$463.4M
$38.7M
Q2 25
$342.1M
$49.7M
Q1 25
$260.9M
$24.7M
Q4 24
$290.8M
Q3 24
$350.3M
$22.6M
Q2 24
$327.7M
Q1 24
$337.3M
$20.1M
Stockholders' Equity
ASTH
ASTH
REAX
REAX
Q4 25
$779.3M
Q3 25
$775.5M
$53.6M
Q2 25
$765.5M
$49.2M
Q1 25
$745.4M
$32.8M
Q4 24
$712.7M
Q3 24
$704.6M
$29.8M
Q2 24
$678.9M
Q1 24
$653.5M
$25.6M
Total Assets
ASTH
ASTH
REAX
REAX
Q4 25
$2.2B
Q3 25
$2.2B
$145.2M
Q2 25
$1.4B
$149.4M
Q1 25
$1.3B
$100.5M
Q4 24
$1.4B
Q3 24
$1.3B
$102.5M
Q2 24
$1.3B
Q1 24
$1.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
REAX
REAX
Operating Cash FlowLast quarter
$-2.9M
$8.8M
Free Cash FlowOCF − Capex
$-6.0M
$8.4M
FCF MarginFCF / Revenue
-0.6%
1.5%
Capex IntensityCapex / Revenue
0.3%
0.1%
Cash ConversionOCF / Net Profit
-0.44×
TTM Free Cash FlowTrailing 4 quarters
$104.5M
$71.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
REAX
REAX
Q4 25
$-2.9M
Q3 25
$10.0M
$8.8M
Q2 25
$90.9M
$41.0M
Q1 25
$16.6M
$15.9M
Q4 24
$-10.9M
Q3 24
$34.0M
$7.2M
Q2 24
$23.2M
Q1 24
$6.0M
$21.5M
Free Cash Flow
ASTH
ASTH
REAX
REAX
Q4 25
$-6.0M
Q3 25
$7.4M
$8.4M
Q2 25
$89.5M
$40.8M
Q1 25
$13.6M
$15.7M
Q4 24
$-13.5M
Q3 24
$31.7M
$6.8M
Q2 24
$20.4M
Q1 24
$5.6M
$21.4M
FCF Margin
ASTH
ASTH
REAX
REAX
Q4 25
-0.6%
Q3 25
0.8%
1.5%
Q2 25
13.7%
7.5%
Q1 25
2.2%
4.4%
Q4 24
-2.0%
Q3 24
6.6%
1.8%
Q2 24
4.2%
Q1 24
1.4%
10.7%
Capex Intensity
ASTH
ASTH
REAX
REAX
Q4 25
0.3%
Q3 25
0.3%
0.1%
Q2 25
0.2%
0.0%
Q1 25
0.5%
0.1%
Q4 24
0.4%
Q3 24
0.5%
0.1%
Q2 24
0.6%
Q1 24
0.1%
0.0%
Cash Conversion
ASTH
ASTH
REAX
REAX
Q4 25
-0.44×
Q3 25
26.69×
Q2 25
9.65×
27.13×
Q1 25
2.48×
Q4 24
Q3 24
2.11×
Q2 24
1.21×
Q1 24
0.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

REAX
REAX

Segment breakdown not available.

Related Comparisons